E-SELECTIN AS A BIOMARKER IN FEMALE PATIENTS WITH Β-THALASSEMIA IN AL- NAJAF PROVENCE, IRAQ
E-selectin, as identified (CD62E), is expressed on endothelial cells after stimulation with inflammation cytokines. β-Thalassemia diseases (βT) and early diagnosis are of utmost significance in the entire world population. This study was performed in the Thalassemia Center of the Al-Zahraa Educational Hospital in Al-Najaf Province, Iraq, on sixty-nine with β-thalassemia (54 βT major and 15 βT Intermedia) aged 8-40 years who transfused blood. Compared to 20 healthy volunteers as a control group. In both βT patients and healthy groups were assessed serum E-selectin levels. It was investigated the relationship with RBC, Hb, PCV, WBC, PLT, BMI, splenic status, iron, and ferritin levels. The results revealed a significant (P<0.05) decreased values of HB, RBC, P.C.V, and BMI. In contrast, values of WBC, PLT, Iron, and Ferritin were significantly increased in βT patients as compared to the healthy control groups. A significant (P<0.05) increase in serum E- Selectin level in βT patients (20.55±0.47) ng/ml to compare with the healthy group (9.16±0.50) ng/ml. Furthermore, it was a significant decrease in groups of βT major (19.87±0.42) ng/ml more than in βT intermedia (23±1.42) ng/ml. E-Selectin revealed a significant increase (P<0.05) in progress age and associated with splenectomies and underweight groups compared to splenectomies and the normal weight groups, respectively. Also, E-Selectin levels significantly positively correlated with WBC, PLT value, iron, and Ferritin levels. However, it was no significant with RBC, PCV, Hb. As a conclusion from this study, E- Selectin is an important biomarker in β-thalassemia patients can be identified as the complications associated with iron overload, inflammatory process, and endothelial dysfunction in βT disease.
Read ArticleUNRAVELING THE COMPLEXITIES OF CARDIOVASCULAR MEDICINE: A CONVERSATION WITH DR. PETER MCCULLOUGH (EXTENDED EN-US VERSION)
Background: This interview covers Dr. Peter McCullough’s medical career, experience as an editor of medical journals, and his expertise in areas such as cardiomyopathy, myocarditis, and pericarditis. Aims: The primary aim is to understand Dr. McCullough’s perspectives on various medical topics, including his journey as a cardiologist, the importance of peer review, the phenomenon of Pheidippides cardiomyopathy, the differences between myocarditis and pericarditis, and the significance of ethical principles like the Nuremberg Code and the Declaration of Helsinki. Additionally, the interview aims to explore his concerns about censorship during the COVID-19 pandemic. Methods: The interview follows a question-and-answer format, with the interviewer posing questions to Dr. McCullough on various topics related to his medical career, research interests, and ethical considerations. Results: Dr. McCullough shares his insights on topics such as cardiomyopathy, myocarditis, and pericarditis, emphasizing the importance of peer review, identifying potential biases, and balancing scientific rigor with timely dissemination of findings. He also highlights the significance of the Nuremberg Code and the Declaration of Helsinki in ensuring informed consent and preventing coercion in medical research and treatment. Discussion: Dr. McCullough expresses concerns about censorship during the COVID-19 pandemic, which he believes impacted the ability of medical professionals to freely discuss and disseminate health-related information. He also discusses the potential role of COVID-19 vaccines in causing myocarditis and the need for transparent communication about treatment options and potential complications. Conclusion: The interview provides valuable insights from Dr. McCullough’s extensive medical experience and expertise, covering a range of topics from cardiovascular conditions to ethical principles and the challenges posed by censorship during the COVID-19 pandemic.
Read ArticleNATURAL EXTRACTS AS A PROMISING SOLUTION FOR GRAM-POSITIVE ANTIBIOTIC RESISTANCE: A COMPREHENSIVE REVIEW
Background: Antibiotic resistance is currently one of the biggest problems in public health. Infectious diseases are the second human death cause, and the emergence of antimicrobial-resistant bacteria increases mortality and morbidity rates. There is a growing clinical need for the development of new antibiotics. In this line, WHO issued an alert about 12 bacteria with an urgent need to develop new antibiotics. Aims: This review aims to analyze the current knowledge of their antibacterial activity against the gram-positive pathogens listed by WHO and their extraction techniques. Methods: We systematically reviewed the literature in PubMed, searching publications describing the use of natural extracts as antibiotics over bacteria. The exclusion criteria consisted of limiting papers on natural extracts tested over the bacteria culture related to eleven selected bacteria, according to an alert issued by WHO in 2017, and seven plant extracts. Results: All the gram-positive bacteria present in the WHO alert have been treated, with different degrees of advance, with some of the plant extracts and plant-based compounds reviewed. Currently, they are in the preclinical stage. Edible herbs are more often used, as well as artemisia and wine byproducts. Discussion: Natural products based on plants have shown to be efficient in inhibiting bacterial growth, even in antibiotic-resistant strains. The classical extraction methods are still in use and have been improved with the available technology to improve efficiency and yield. Conclusions: Ongoing evidence shows that plant extracts and plant-based compounds are effective as antibacterial, with minimal effects on the host cell, a promising antibiotic source. Furthermore, they are sustainable, environmentally friendly, and renewable.
Read Article